{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:15:54Z","timestamp":1783739754472,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00066-021-01845-7","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T21:11:47Z","timestamp":1630703507000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Significance of liver metastasis volume in breast cancer patients treated with stereotactic body radiotherapy"],"prefix":"10.1007","volume":"198","author":[{"given":"Ezgi","family":"Oymak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-9021","authenticated-orcid":false,"given":"Cem","family":"Onal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"1845_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray\u00a0F, Ferlay\u00a0J, Soerjomataram\u00a0I, Siegel\u00a0RL, Torre\u00a0LA, Jemal\u00a0A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185\u00a0countries. CA Cancer J Clin 68:394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492","journal-title":"CA Cancer J Clin"},{"key":"1845_CR2","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdn424","volume":"19","author":"R Largillier","year":"2008","unstructured":"Largillier\u00a0R, Ferrero\u00a0JM, Doyen\u00a0J, Barriere\u00a0J, Namer\u00a0M, Mari\u00a0V et\u00a0al (2008) Prognostic factors in 1,038\u00a0women with metastatic breast cancer. Ann Oncol 19:2012\u20132019. https:\/\/doi.org\/10.1093\/annonc\/mdn424","journal-title":"Ann Oncol"},{"key":"1845_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/jco.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman\u00a0S, Weichselbaum\u00a0RR (1995) Oligometastases. J\u00a0Clin Oncol 13:8\u201310. https:\/\/doi.org\/10.1200\/jco.1995.13.1.8","journal-title":"J Clin Oncol"},{"key":"1845_CR4","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/s0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S, Gaede\u00a0S, Louie\u00a0AV, Haasbeek\u00a0C et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a\u00a0randomised, phase 2, open-label trial. Lancet 393:2051\u20132058. https:\/\/doi.org\/10.1016\/s0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"1845_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00270-008-9384-7","volume":"32","author":"TF Jakobs","year":"2009","unstructured":"Jakobs\u00a0TF, Hoffmann\u00a0RT, Schrader\u00a0A, Stemmler\u00a0HJ, Trumm\u00a0C, Lubienski\u00a0A et al (2009) CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 32:38\u201346. https:\/\/doi.org\/10.1007\/s00270-008-9384-7","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1845_CR6","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.ijrobp.2011.08.036","volume":"83","author":"MT Milano","year":"2012","unstructured":"Milano\u00a0MT, Katz\u00a0AW, Zhang\u00a0H, Okunieff\u00a0P (2012) Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878\u2013886. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.08.036","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1845_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1148\/radiol.2533081968","volume":"253","author":"MF Meloni","year":"2009","unstructured":"Meloni\u00a0MF, Andreano\u00a0A, Laeseke\u00a0PF, Livraghi\u00a0T, Sironi\u00a0S, Lee\u00a0FT Jr (2009) Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation\u2014intermediate and long-term survival rates. Radiology 253:861\u2013869. https:\/\/doi.org\/10.1148\/radiol.2533081968","journal-title":"Radiology"},{"key":"1845_CR8","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00270-016-1301-x","volume":"39","author":"M Barral","year":"2016","unstructured":"Barral\u00a0M, Auperin\u00a0A, Hakime\u00a0A, Cartier\u00a0V, Tacher\u00a0V, Otmezguine\u00a0Y et\u00a0al (2016) Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients. Cardiovasc Intervent Radiol 39:885\u2013893. https:\/\/doi.org\/10.1007\/s00270-016-1301-x","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1845_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.semradonc.2017.02.001","volume":"27","author":"EL Pollom","year":"2017","unstructured":"Pollom\u00a0EL, Chin\u00a0AL, Diehn\u00a0M, Loo\u00a0BW, Chang\u00a0DT (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27:197\u2013208. https:\/\/doi.org\/10.1016\/j.semradonc.2017.02.001","journal-title":"Semin Radiat Oncol"},{"key":"1845_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.rpor.2016.10.003","volume":"22","author":"A M\u00e9ndez Romero","year":"2017","unstructured":"M\u00e9ndez Romero\u00a0A, Keskin-Cambay\u00a0F, van Os\u00a0RM, Nuyttens\u00a0JJ, Heijmen\u00a0BJM, IJzermans\u00a0JNM et al (2017) Institutional experience in the treatment of colorectal liver metastases with stereotactic body radiation therapy. Rep Pract Oncol Radiother 22:126\u2013131. https:\/\/doi.org\/10.1016\/j.rpor.2016.10.003","journal-title":"Rep Pract Oncol Radiother"},{"key":"1845_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00432-014-1833-x","volume":"141","author":"M Scorsetti","year":"2015","unstructured":"Scorsetti\u00a0M, Comito\u00a0T, Tozzi\u00a0A, Navarria\u00a0P, Fogliata\u00a0A, Clerici\u00a0E et\u00a0al (2015) Final results of a\u00a0phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J\u00a0Cancer Res Clin Oncol 141:543\u2013553. https:\/\/doi.org\/10.1007\/s00432-014-1833-x","journal-title":"J Cancer Res Clin Oncol"},{"key":"1845_CR12","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1200\/jco.2008.19.6329","volume":"27","author":"KE Rusthoven","year":"2009","unstructured":"Rusthoven\u00a0KE, Kavanagh\u00a0BD, Cardenes\u00a0H, Stieber\u00a0VW, Burri\u00a0SH, Feigenberg\u00a0SJ et al (2009) Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases. J\u00a0Clin Oncol 27:1572\u20131578. https:\/\/doi.org\/10.1200\/jco.2008.19.6329","journal-title":"J Clin Oncol"},{"key":"1845_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.breast.2018.09.006","volume":"42","author":"C Onal","year":"2018","unstructured":"Onal\u00a0C, Guler\u00a0OC, Yildirim\u00a0BA (2018) Treatment outcomes of breast cancer liver metastasis treated with stereotactic body radiotherapy. Breast 42:150\u2013156. https:\/\/doi.org\/10.1016\/j.breast.2018.09.006","journal-title":"Breast"},{"key":"1845_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3389\/fonc.2020.00347","volume":"10","author":"TS Su","year":"2020","unstructured":"Su\u00a0TS, Liang\u00a0P, Zhou\u00a0Y, Huang\u00a0Y, Cheng\u00a0T, Qu\u00a0S et al (2020) Stereotactic body radiation therapy vs. transarterial chemoembolization in inoperable barcelona clinic liver cancer stage a\u00a0hepatocellular carcinoma: a retrospective, propensity-matched analysis. Front Oncol 10:347. https:\/\/doi.org\/10.3389\/fonc.2020.00347","journal-title":"Front Oncol"},{"key":"1845_CR15","doi-asserted-by":"publisher","first-page":"e0206381","DOI":"10.1371\/journal.pone.0206381","volume":"13","author":"BG Jun","year":"2018","unstructured":"Jun\u00a0BG, Kim\u00a0SG, Kim\u00a0YD, Cheon\u00a0GJ, Han\u00a0KH, Yoo\u00a0JJ et\u00a0al (2018) Combined therapy of transarterial chemoembolization and stereotactic body radiation therapy versus transarterial chemoembolization for \u3008\/=5\u202fcm hepatocellular carcinoma: propensity score matching analysis. PLoS ONE 13:e206381. https:\/\/doi.org\/10.1371\/journal.pone.0206381","journal-title":"PLoS ONE"},{"key":"1845_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.radonc.2018.12.013","volume":"131","author":"N Kim","year":"2019","unstructured":"Kim\u00a0N, Kim\u00a0HJ, Won\u00a0JY, Kim\u00a0DY, Han\u00a0KH, Jung\u00a0I et\u00a0al (2019) Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol 131:81\u201387. https:\/\/doi.org\/10.1016\/j.radonc.2018.12.013","journal-title":"Radiother Oncol"},{"key":"1845_CR17","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijrobp.2012.12.021","volume":"86","author":"M Scorsetti","year":"2013","unstructured":"Scorsetti\u00a0M, Arcangeli\u00a0S, Tozzi\u00a0A, Comito\u00a0T, Alongi\u00a0F, Navarria\u00a0P et\u00a0al (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a\u00a0phase 2 trial. Int J Radiat Oncol Biol Phys 86:336\u2013342. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.12.021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1845_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clcc.2017.03.006","volume":"16","author":"P Berkovic","year":"2017","unstructured":"Berkovic\u00a0P, Gulyban\u00a0A, Nguyen\u00a0PV, Dechambre\u00a0D, Martinive\u00a0P, Jansen\u00a0N et\u00a0al (2017) Stereotactic robotic body radiotherapy for patients with unresectable hepatic oligorecurrence. Clin Colorectal Cancer 16:349\u2013357.e1. https:\/\/doi.org\/10.1016\/j.clcc.2017.03.006","journal-title":"Clin Colorectal Cancer"},{"key":"1845_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13014-018-0969-2","volume":"13","author":"A Mahadevan","year":"2018","unstructured":"Mahadevan\u00a0A, Blanck\u00a0O, Lanciano\u00a0R, Peddada\u00a0A, Sundararaman\u00a0S, D\u2019Ambrosio\u00a0D et al (2018) Stereotactic body radiotherapy (SBRT) for liver metastasis\u2014clinical outcomes from the international multi-institutional RSSearch(R) patient registry. Radiat Oncol 13:26. https:\/\/doi.org\/10.1186\/s13014-018-0969-2","journal-title":"Radiat Oncol"},{"key":"1845_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3389\/fonc.2020.00987","volume":"10","author":"F Weykamp","year":"2020","unstructured":"Weykamp\u00a0F, Konig\u00a0L, Seidensaal\u00a0K, Forster\u00a0T, Hoegen\u00a0P, Akbaba\u00a0S et\u00a0al (2020) Extracranial stereotactic body radiotherapy in oligometastatic or oligoprogressive breast cancer. Front Oncol 10:987. https:\/\/doi.org\/10.3389\/fonc.2020.00987","journal-title":"Front Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01845-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T15:03:00Z","timestamp":1645542180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01845-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01845-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.\u00a0Oymak, O.C.\u00a0Guler, and C.\u00a0Onal declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}